About Cagrilintide

Cagrilintide is a long-acting analogue of amylin, the pancreatic peptide hormone co-secreted with insulin that regulates satiety, gastric emptying, and glucagon suppression. Native amylin has a plasma half-life of ~13 minutes, which makes it useless as a stand-alone therapeutic. Cagrilintide’s modifications (acylation with a fatty-acid chain, amino-acid substitutions) extend the half-life to roughly seven days, enabling once-weekly dosing.

Most of the research interest in Cagrilintide isn’t as a stand-alone compound — it’s as the partner in CagriSema, the combination of Cagrilintide and Semaglutide developed by Novo Nordisk. Combined, the two produce greater weight loss in trial data than Semaglutide alone, with the amylin pathway adding satiety effect on top of the GLP-1 mechanism.

Dosing observed in research literature

Application	Dose	Frequency	Notes
Sensitivity / starting protocol	0.16 mg	Once weekly	Weeks 1–4 of titration
Titration range	0.3 → 1.2 mg	Once weekly	Step up every 4 weeks
Maintenance research dose	2.4 mg	Once weekly	Maximum dose in published trials

Standard research protocol mirrors the trial titration: start at 0.16 mg, double every 4 weeks (0.3, 0.6, 1.2, 2.4 mg) to reach maintenance. Skipping the titration causes severe nausea — the amylin receptors need time to adapt.

Typical reconstitution protocols

Cagrilintide research vials are commonly 5 mg or 10 mg lyophilised:

Vial size	BAC water	Concentration	0.3 mg draw	1.2 mg draw	2.4 mg draw
5 mg	2 mL	2.5 mg/mL	12 units	48 units	96 units
5 mg	2.5 mL	2 mg/mL	15 units	60 units	120 units (2 draws)
10 mg	2 mL	5 mg/mL	6 units	24 units	48 units
10 mg	4 mL	2.5 mg/mL	12 units	48 units	96 units

The 10 mg vial + 2 mL BAC water (5 mg/mL) is the cleanest setup — keeps draws within a single U-100 barrel even at the 2.4 mg maintenance dose.

Half-life and frequency

Plasma half-life of Cagrilintide is ~7 days — long enough that once-weekly dosing produces a near-steady plasma concentration. The acylation-mediated albumin binding is what extends the half-life from amylin’s native ~13 minutes.

Steady state is reached after approximately 5–6 weekly doses (5 × half-life rule). Research protocols typically administer the weekly dose on the same day of the week to keep absorption rhythm consistent — most studies use a Sunday or Monday injection day.

Storage and shelf life

Lyophilised: store at 2–8°C refrigerated. Reconstituted with bacteriostatic water: stable for up to 28 days refrigerated — convenient given the once-weekly dosing means one vial typically lasts 4+ weeks before needing replacement. Never freeze a reconstituted vial.

Frequently asked questions

Can Cagrilintide be combined with Semaglutide?

Yes — that combination (CagriSema) is the primary research interest for Cagrilintide. Studied protocols typically titrate both compounds in parallel: 0.16 → 0.3 → 0.6 → 1.2 → 2.4 mg of each, weekly. The combined effect on weight loss is greater than either alone in trial data.

Should Cagrilintide be combined with Tirzepatide or Retatrutide?

These combinations haven’t been studied in formal trials. Tirzepatide and Retatrutide are already multi-receptor agonists (Tirzepatide hits GLP-1 + GIP; Retatrutide hits GLP-1 + GIP + glucagon). Adding Cagrilintide adds amylin receptor activity on top — theoretically complementary, but the combined GI side-effect load increases substantially. Caution warranted.

Why is titration so important?

Amylin receptors in the gut and CNS desensitise rapidly to gradual exposure but produce significant nausea when hit at full dose without acclimatisation. Trial dropout rates without titration are dramatically higher than with proper titration. The 4-week step-up at each level allows receptor adaptation.

How long until effects are measurable?

Satiety effects are typically reportable within 1–2 weeks of starting. Weight-loss endpoints in trials register meaningfully at 12+ weeks, with continuing reduction observed through 28-week and 68-week trial endpoints.

What are the most-reported side effects?

Nausea (especially during titration), reduced appetite, constipation, occasional vomiting. Side-effect profile mirrors GLP-1 agonists but with somewhat earlier onset due to amylin’s direct gastric-emptying effect. Hypoglycaemia is rare since Cagrilintide doesn’t directly stimulate insulin release.

What injection site is used for Cagrilintide?

Subcutaneous abdominal injection is standard. Thigh and deltoid are acceptable alternatives. Site rotation across weekly injections is documented in trial protocols.

Related compounds

Cagrilintide sits in the metabolic research category. Closely related: Semaglutide (the standard CagriSema partner — GLP-1 agonist), Tirzepatide (dual GLP-1 / GIP), Retatrutide (triple agonist). For full category overview: Weight Loss & Metabolic Research Compounds.